

Date: October 09, 2025

To,
The Manager- Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E), Mumbai
- 400 051

SYMBOL: REMUS

Dear Sir/Madam,

Sub: Disclosure under Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2025

In compliance with Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants), Regulations, 2018, please find enclosed herewith the Reconciliation of Share Capital Audit Report, dated October 08, 2025, duly signed and issued by Mr. Tapan Shah, Company Secretary in Practice, for the quarter ended September 30, 2025.

This is for your information and records.

Thanking you.
For, Remus Pharmaceuticals Limited

Deval Patel
Company Secretary and Compliance Officer
ICSI Membership No.: A60090

Encl: As Above

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

To,
The Board of Directors,
REMUS PHARMACEUTICALS LIMITED,
1101 to 1103, South Tower, One 42,
B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad,
Gujarat, India, 380054.

RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

CIN : L24232GJ2015PLC084536
Authorised Capital : Rs. 12,50,00,000

I have examined the Register of Members, beneficiary details given by the Depositories and other records / documents maintained by **M/s. REMUS PHARMACEUTICALS LIMITED**, having its Registered Office at 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad, Gujarat, India, 380054 for issuing Certificate, in accordance with Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 read with Circular D&CC/FITTC/CIR-16/2002 dated December 31, 2002 issued by the Securities and Exchange Board of India ("SEBI"). To the best of my knowledge and according to the information and explanation given to me and as per the record received through mail and examined by me, I hereby certify that for the quarter ended 30th September, 2025, the details of position of Company's Capital Structure, it's Equity shares position with NSDL, CDSL and in Physical form, Demat activity carried out and any pending Demat status and other details are as under:

1	For Quarter Ended	30/09/2025
2	ISIN	INE005T01011
3	Face Value	Rs. 10/- per Share
4	Name of the Company	REMUS PHARMACEUTICALS LIMITED
5	Registered Office Address	1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad, Gujarat, India, 380054.
6	Correspondence Address	-- Same as above --
7	Telephone & Fax Nos.	Tel. 079-29999857
8	Email Address	cs@remuspharma.com legal@remuspharma.com
9	Name of the Stock Exchanges where the Company's Securities are listed with scrip code	National Stock Exchange of India Ltd.- SME emerge platform (Symbol- REMUS)
10	Issued Equity Share Capital	No. of Shares 1,17,84,000
11	Listed Equity Capital (as per company records)	1,17,84,000



				No. of shares	% of issued Capital		
12	Held in dematerialized form in NSDL			18,41,500	15.63		
13	Held in dematerialized form in CDSL			99,42,500	84.37		
14	Physical			0	0.00		
15	Total No. of Shares (12+13+14)			1,17,84,000	100.00		
16	Reason for difference, if any, between (10&11),(11 & 15)			N.A.			
17	Certifying details of changes in share capital during the quarter under consideration as per Table below :						
Particulars		No. of Shares	Applied/ not Applied for Listing	Listed on Stock Exchanges (Specify Names)	Whether intimate d to CDSL	Whether intimated to NSDL	In-principle Approval Pending for SE (Specify Names)
Allotment of equity shares through Bonus issue in ratio of 1:1		58,92,000	Listing and trading Approval received	National Stock Exchange of India Limited (SME)	Yes	Yes	NA
18	Register of Members is updated (YES/NO) if not, updated up to which date				Yes		
19	Reference of previous quarter with regards to excess dematerialized shares, if any				-- N.A. --		
20	Has the company resolved the matter mentioned in point no. 19 above in the current quarter? If not, reason why?				-- N.A. --		
21	Mentioned the total no. of requests, confirmed after 21 days and the total no. of requests pending beyond 21 days(in both cases, from the date of DRN & confirmed by the Registrar is taken), with the reasons for delay :						
Total No. of demat requests			No. of requests		No. of shares		Reasons for delay
			NSDL	CDSL	NSDL	CDSL	N.A.
Confirmed after 21 days			--	--	--	--	
Pending for more than 21 Days			--	--	--	--	
22	Name, Telephone & Fax No. of Compliance Officer of the Co.			Ms. Deval Patel, Company Secretary and Compliance officer Tel : 079-2999 9857 Email : cs@remuspharma.com			



23	Name, Address, Tel. & Fax No. of the Company Secretary in whole-time practice	Mr. Tapan Shah (CP No.2839) 816-818, Anand Mangal-3, Nr. Doctor House, Ellisbridge, Ahmedabad-6 Tel.: 40024320 E-mail : info@tapanshah.in
24	Appointment of Common Agency for Share Registry Work (Name & Address)	MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited) 5th Floor, 506 to 508, Amarnath Business Centre – I (ABC - I), Nr. St. Xavier's College Corner, Off. C.G.Road, Navrangpura, Ahmedabad- 380009 Tel-079-26465179. E-mail : investor.helpdesk@in.mpms.mufg.com
25	Any other detail that the Co. Secretary may like to provide (e.g. BIFR Co., delisting from SE, Company changed its name etc.	<ul style="list-style-type: none"> During the quarter, Company has allotted 58,92,000 (Fifty-Eight Lakhs Ninety-Two Thousand only) Equity Shares of Rs. 10/- (Rupees Ten only) each amounting to Rs. 5,89,20,000/- (Rupees Five Crore Eighty- Nine Lakhs Twenty Thousand only) as Bonus Equity Shares to the equity shareholders of the Company, in the ratio of 1:1 i.e., 1 (One) new fully paid-up Equity Share of Rs. 10/- (Rupees Ten only) each for every 1 (One) existing fully paid-up Equity Share of Rs. 10/- (Rupees Ten only) each on July 07, 2025 and the listing and trading of shares commenced from July 08, 2025. Post allotment of Bonus Equity Shares, the listed equity capital the Company is 1,17,84,000 equity shares. The Company has incorporated new Subsidiary Company, namely "Espee Global Clinical Trial Services Private Limited" as on July 24, 2025. In AGM dated September 25, 2025, Mr. Arpit Deepakkumar Shah (DIN: 07214641) was reappointed as a Managing Director and Ms. Roma Vinodbhai Shah (DIN: 07214632) was reappointed as a Whole Time Director of the Company.



816-818, Anand Mangal – 3, Opp. Core House,
Nr. Doctor House, Ellisbridge, Ahmedabad-380006
Phone: (O) 40024320
E-mail: info@tapanshah.in

Place: Ahmedabad.
Date : 08/10/2025

Signature: TAPAN RAJNIKANT SHAH
Name of Company Secretary: TAPAN SHAH
C. P. Number: 2839
UDIN: F004476G001486594

Digitally signed by
TAPAN RAJNIKANT
SHAH
Date: 2025.10.08
11:06:39 +05'30'

Note:

Above report was prepared based on the softcopy of the papers/ report/ documents provided by the Share Registry of the Company, i.e. MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited).

